New drug shows promise in controlling rare skin cancers
NCT ID NCT01352520
First seen Feb 01, 2026 · Last updated May 01, 2026 · Updated 9 times
Summary
This study tests a drug called brentuximab vedotin in 79 people with three types of skin lymphoma that have a specific marker (CD30). The goal is to see if the drug can shrink or control the cancer. Participants receive the drug through an IV every three weeks, and researchers track how well the tumors respond and how long it takes for the disease to worsen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.